Literature DB >> 9853791

Review of integrated mental health and substance abuse treatment for patients with dual disorders.

R E Drake1, C Mercer-McFadden, K T Mueser, G J McHugo, G R Bond.   

Abstract

Patients with severe mental disorders such as schizophrenia and co-occurring substance use disorders traditionally received treatments for their two disorders from two different sets of clinicians in parallel treatment systems. Dissatisfaction with this clinical tradition led to the development of integrated treatment models in which the same clinicians or teams of clinicians provide substance abuse treatment and mental health treatment in a coordinated fashion. We reviewed 36 research studies on the effectiveness of integrated treatment for dually diagnosed patients. Studies of adding dual-disorders groups to traditional services, studies of intensive integrated treatments in controlled settings, and studies of demonstration projects have thus far yielded disappointing results. On the other hand, 10 recent studies of comprehensive, integrated outpatient treatment programs provide encouraging evidence of the programs' potential to engage dually diagnosed patients in services and to help them reduce substance abuse and attain remission. Outcomes related to hospital use, psychiatric symptoms, and other domains are less consistent. Several program features appear to be associated with effectiveness: assertive outreach, case management, and a longitudinal, stage-wise, motivational approach to substance abuse treatment. Given the magnitude and severity of the problem of dual disorders, more controlled research on integrated treatment is needed.

Entities:  

Mesh:

Year:  1998        PMID: 9853791     DOI: 10.1093/oxfordjournals.schbul.a033351

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  75 in total

1.  Social costs of untreated opioid dependence.

Authors:  R Wall; J Rehm; B Fischer; B Brands; L Gliksman; J Stewart; W Medved; J Blake
Journal:  J Urban Health       Date:  2000-12       Impact factor: 3.671

Review 2.  Managing comorbid schizophrenia and substance abuse.

Authors:  R E Drake; K T Mueser
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

3.  A family intervention program for dual disorders.

Authors:  Kim T Mueser; Lindy Fox
Journal:  Community Ment Health J       Date:  2002-06

4.  Longitudinal effects of integrated treatment on alcohol use for persons with serious mental illness and substance use disorders.

Authors:  S E Herman; K A Frank; C T Mowbray; K M Ribisl; W S Davidson; B BootsMiller; L Jordan; A L Greenfield; D Loveland; D A Luke
Journal:  J Behav Health Serv Res       Date:  2000-08       Impact factor: 1.505

5.  Remote "hovering" with individuals with psychotic disorders and substance use: feasibility, engagement, and therapeutic alliance with a text-messaging mobile interventionist.

Authors:  Dror Ben-Zeev; Susan M Kaiser; Izabela Krzos
Journal:  J Dual Diagn       Date:  2014

6.  Use of the Transtheoretical Model for individuals with co-occurring disorders.

Authors:  Deborah S Finnell
Journal:  Community Ment Health J       Date:  2003-02

7.  Adapting a substance abuse court diversion model for felony offenders with co-occurring disorders: initial implementation.

Authors:  Nahama Broner; Huy Nguyen; Anne Swern; Stephen Goldfinger
Journal:  Psychiatr Q       Date:  2003

8.  A call for standardized definition of dual diagnosis.

Authors:  Kathyrn Hryb; Rob Kirkhart; Rebecca Talbert
Journal:  Psychiatry (Edgmont)       Date:  2007-09

9.  Implementation and Outcomes of Forensic Housing First Programs.

Authors:  Liat S Kriegel; Benjamin F Henwood; Todd P Gilmer
Journal:  Community Ment Health J       Date:  2015-10-05

10.  Training in Substance-Related and Addictive Disorders, Part 2: Updated Curriculum Guidelines.

Authors:  David Crockford; Gilles Fleury; Robert Milin; Leslie Buckley; Dara Charney; Tony P George; Nady el-Guebaly
Journal:  Can J Psychiatry       Date:  2015-12       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.